A carregar...
Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
In patients with glioblastoma, antiangiogenic therapy with bevacizumab (BEV) has been shown to improve progression-free survival (PFS), but not overall survival (OS). Especially in patients with an unusual infiltrative phenotype as seen in multifocal glioblastoma, the use of BEV therapy is still mor...
Na minha lista:
| Publicado no: | Int J Mol Sci |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5713435/ https://ncbi.nlm.nih.gov/pubmed/29156610 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18112469 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|